Business Context and Reporting Period
Company: MediWound Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter ended March 31, 2021
Filing Date: May 5, 2021
This filing incorporates by reference a press release announcing First Quarter 2021 financial results and un-audited condensed consolidated interim financial statements provided to Clal Biotechnology Industries Ltd. (CBI) pursuant to an Information Rights Agreement.
Key Financial Metrics
The provided text serves as a cover document and exhibit index. It references the existence of financial results in Exhibit 99.1 and financial statements in Exhibit 99.2 but does not contain the specific numerical data within the body of this text.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in the provided filing text. They are contained in the referenced exhibits (99.1 and 99.2) which are not included in the input.
Material Changes
The filing text does not provide specific comparative data or describe material changes versus the prior comparable period. Such analysis is contained within the referenced press release and financial statements.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release containing senior management commentary, though the specific quotes are excluded from the incorporation by reference clause in the text provided.
Outlook and Guidance: No specific forward-looking guidance or outlook is detailed in this cover document.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2021 revenue, net income, and cash flow figures.
- Review Exhibit 99.2 (Un-Audited Financial Statements) for detailed balance sheet and income statement data as of March 31, 2021.
- Verify year-over-year growth rates and margin trends in the attached exhibits.
- Confirm the status of the Information Rights Agreement with Clal Biotechnology Industries Ltd. (CBI) and any associated obligations.